The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts to help oncologists determine when and how to best use immunotherapy to treat their patients. The guidelines are developed using a systematic process to ensure the recommendations are unbiased, relevant, and facilitate clinical decision-making. The guidelines will be evaluated and updated on an ongoing basis.
Prior to publication of each guideline, a Member Comment period is launched to allow SITC members to review a draft copy of the guideline and provide feedback, with the goal of further improving the draft. Click here to learn more about the Member Comment period.
In response to the ever-growing demand for expert guidance on the optimal use of immunotherapy treatments, our Cancer Immunotherapy Guidelines committees have developed consensus statements for cutaneous melanoma, genitourinary malignancies (renal, prostate and bladder carcinoma) and hematologic malignancies (multiple myeloma, lymphoma and acute leukemia).
New guidelines for non-small cell lung cancer and head and neck cancers are currently underway. These disease-specific Cancer Immunotherapy Guidelines offer a vital resource for the practicing oncology community.
Published May 30, 2018 in Journal for ImmunoTherapy of Cancer (JITC) as "An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0."
Published Nov. 15, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma."
Published Dec. 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma."
Published Aug. 15, 2017 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma."
Published Dec. 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia."
Key points from SITC's Cancer Immunotherapy Guidelines have been distilled into Pocket Guides. These condensed, easily accessible versions of the full Cancer Immunotherapy Guidelines are a quick-reference tool available in both digital and print.
Download SITC's Cancer Immunotherapy Pocket Guides on any desktop or mobile device free today.*
*Available only through the Guideline Central App.
ORDER Digital/Print Guides
SITC follows the 2011 Institute of Medicine’s “Standards for Developing Trustworthy Clinical Practice Guidelines” to assure a fair, transparent and balanced process for creating each consensus statement; therefore, each Cancer Immunotherapy Guidelines subcommittee comprises a comprehensive mix of academic physicians and researchers, nurses, patients, and patient advocates invited from institutions across the United States.
Each expert committee addresses knowledge gaps in our understanding of immunotherapy treatments for their disease specialty, and develops evidence-based recommendations by evaluating the published literature and providing their opinions on key issues, documenting alternative opinions when they occur.
This message was posted by a user wishing to remain anonymous Given that each cytokine degrades at different points in the media...while setting up a multiplex in vitro cytokine profiling assay, (with PBMCs post treatment) what is the best time point ...
Dear colleagues, Dear participants,
I would like to invite you to attend and participate actively in our
ISOBM (International Society of Oncology and BioMarkers) 2018 CONGRESS, to be held in Hamburg, Germany, on November 24 - 27, 2018. ...
Animal models have shown intestinal microbiota are crucial for therapeutic efficacy for CTLA4 blockade ( has decreased tumor size) and anti-PD1 psychotherapies.That the microbiome may be a target that can be modulated to enhance treatment responses. Theoretically, ...
The human microbiome: an emerging paradigm for better health
The human enteric nervous system (ENS), an off shoot of the autonomic nervous system, ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com